Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS)
CUSIP: 03771D102
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 12,584,892
- Total 13F shares
- 395,700
- Share change
- -4,283
- Total reported value
- $648,947
- Price per share
- $1.64
- Number of holders
- 7
- Value change
- -$15,296
- Number of buys
- 6
- Number of sells
- 4
Quarterly Holders Quick Answers
What is CUSIP 03771D102?
CUSIP 03771D102 identifies APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q3 2025
Recent filing periods for CUSIP 03771D102:
Top shareholders of APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Inscobee Inc. |
3/4/5
|
10%+ Owner |
34%
|
4,316,618
|
$8,805,900 | — | 12 May 2025 | |
| Ayrton Capital LLC |
13D/G
|
— |
10%
|
1,397,021
|
$2,612,429 | $0 | 31 Dec 2025 | |
| Erik C. Emerson |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
965,000
mixed-class rows
|
$1,312,500 | — | 15 Oct 2025 | |
| Christopher Kim |
3/4/5
|
Chairman and CMO, Director |
—
mixed-class rows
|
280,500
mixed-class rows
|
$485,625 | — | 15 Oct 2025 | |
| Hemenway Trust Co LLC |
13F
|
Company |
2%
|
250,000
|
$445,000 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.47%
|
58,992
|
$105,005 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
30,754
|
$54,741 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.22%
|
27,893
|
$49,650 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.15%
|
18,735
|
$33,348 | — | 30 Sep 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.11%
|
13,572
|
$24,000 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
29
|
$52 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
8
|
$14 | — | 30 Sep 2025 | |
| Jakap Koo |
3/4/5
|
Director |
—
mixed-class rows
|
653,885
mixed-class rows
|
— | — | 11 Nov 2025 | |
| Bennett Weintraub |
3/4/5
|
Director |
—
class O/S missing
|
10,000
|
— | — | 11 Nov 2025 | |
| Carol A. O'Donnell |
3/4/5
|
Director |
—
class O/S missing
|
10,000
|
— | — | 11 Nov 2025 | |
| Elona Kogan |
3/4/5
|
Director |
—
class O/S missing
|
10,000
|
— | — | 11 Nov 2025 | |
| Hankil Yoon |
3/4/5
|
Director |
—
class O/S missing
|
10,000
|
— | — | 11 Nov 2025 |
Institutional Holders of Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) as of Q4 2025
As of 31 Dec 2025,
Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) was held by
7 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
395,700 shares.
The largest 7 holders included
Hemenway Trust Co LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, JANE STREET GROUP, LLC, UBS Group AG, BANK OF AMERICA CORP /DE/, and Tower Research Capital LLC (TRC).
This page lists
7
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
8
Q4 2025 holders
7
Holder diff
-1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.